Cereno Scientific receives patent approval in Australia for use of drug candidate CS1
Cereno Scientific has received a new granted patent in Australia. The patent broadens the protection for the use of the drug candidate, CS1, in an important market for the company. The granted patent ”Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors” is the second granted patent in Cereno Scientifics first patent family.“It´s positive that we receive this information, which significantly strengthens the intellectual property rights for CS1 in an important drug market. During the autumn, we have also entered the national phase in just